Creative Medical Gets Safety Approval in FDA-Cleared Back Pain Treatment Trial

MT Newswires Live11-14

Creative Medical Technology (CELZ) said Wednesday its experimental treatment for chronic lower back pain due to degenerative disc disease, CELZ-201, successfully passed an independent interim safety review by the Data Safety Monitoring Board in its clinical trial.

The clearance to proceed with the ADAPT clinical trial, which will evaluate the safety, tolerability and efficacy of CELZ-201, was granted after a safety data review from the first five dosed patients, according to the company.

The experimental drug will be administered intramuscularly and will be compared to placebo in the double-blind, dose-escalation study, Creative Medical added.

Shares of Creative Medical Technology were up 1.1% in recent trading.

Price: 2.79, Change: +0.03, Percent Change: +1.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483830209?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 00:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483830209","market":"sg","top_or_hot":-1,"title":"Creative Medical Gets Safety Approval in FDA-Cleared Back Pain Treatment Trial","media":"MT Newswires Live","content":"<html><body><p> Creative Medical Technology (CELZ) said Wednesday its experimental treatment for chronic lower back pain due to degenerative disc disease, CELZ-201, successfully passed an independent interim safety review by the Data Safety Monitoring Board in its clinical trial.</p><p>The clearance to proceed with the ADAPT clinical trial, which will evaluate the safety, tolerability and efficacy of CELZ-201, was granted after a safety data review from the first five dosed patients, according to the company.</p><p>The experimental drug will be administered intramuscularly and will be compared to placebo in the double-blind, dose-escalation study, Creative Medical added.</p><p>Shares of Creative Medical Technology were up 1.1% in recent trading.</p><p>Price: 2.79, Change: +0.03, Percent Change: +1.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Creative Medical Gets Safety Approval in FDA-Cleared Back Pain Treatment Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCreative Medical Gets Safety Approval in FDA-Cleared Back Pain Treatment Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 00:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Creative Medical Technology (CELZ) said Wednesday its experimental treatment for chronic lower back pain due to degenerative disc disease, CELZ-201, successfully passed an independent interim safety ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELZ","symbol_name":"Creative Med Technology Hldgs","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483830209","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483830209","pubTimestamp":1731513780,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Creative Medical Technology  said Wednesday its experimental treatment for chronic lower back pain due to degenerative disc disease, CELZ-201, successfully passed an independent interim safety review by the Data Safety Monitoring Board in its clinical trial.The clearance to proceed with the ADAPT clinical trial, which will evaluate the safety, tolerability and efficacy of CELZ-201, was granted after a safety data review from the first five dosed patients, according to the company.The experimental drug will be administered intramuscularly and will be compared to placebo in the double-blind, dose-escalation study, Creative Medical added.Shares of Creative Medical Technology were up 1.1% in recent trading.Price: 2.79, Change: +0.03, Percent Change: +1.09","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELZ":"Creative Med Technology Hldgs","BK4139":"生物科技"},"translate_title":"Creative Medical在FDA批准的背痛治疗试验中获得安全批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELZ":0.9},"content_text":"Creative Medical Technology (CELZ) said Wednesday its experimental treatment for chronic lower back pain due to degenerative disc disease, CELZ-201, successfully passed an independent interim safety review by the Data Safety Monitoring Board in its clinical trial.The clearance to proceed with the ADAPT clinical trial, which will evaluate the safety, tolerability and efficacy of CELZ-201, was granted after a safety data review from the first five dosed patients, according to the company.The experimental drug will be administered intramuscularly and will be compared to placebo in the double-blind, dose-escalation study, Creative Medical added.Shares of Creative Medical Technology were up 1.1% in recent trading.Price: 2.79, Change: +0.03, Percent Change: +1.09","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483830209"}